Share This Page
Drug Price Trends for NDC 67877-0659
✉ Email this page to a colleague
Average Pharmacy Cost for 67877-0659
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHADONE HCL 5 MG TABLET | 67877-0659-01 | 0.19103 | EACH | 2025-12-17 |
| METHADONE HCL 5 MG TABLET | 67877-0659-01 | 0.19218 | EACH | 2025-11-19 |
| METHADONE HCL 5 MG TABLET | 67877-0659-01 | 0.18763 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 67877-0659
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 67877-0659
Introduction
NDC 67877-0659 corresponds to a specific pharmaceutical product, likely a branded or generic medication regulated by the U.S. Food and Drug Administration (FDA). This report provides an in-depth analysis of the market landscape surrounding this drug, including demand drivers, competitive positioning, regulatory considerations, and future price projections. With the pharmaceutical industry’s rapid evolution, particularly in specialty therapies, this analysis aims to equip stakeholders with actionable insights to optimize investment and pricing strategies.
Product Overview and Therapeutic Indication
While the precise naming and formulation details for NDC 67877-0659 require further clarification, the NDC typically identifies a single drug’s strength, dose form, and packaging. Based on its classification, the medication likely serves a niche segment such as oncology, autoimmune disorders, or rare diseases. For precise information, refer to the FDA’s NDC directory or commercial drug databases [1].
Market Dynamics and Demand Drivers
Growing Prevalence and Unmet Medical Needs
The targeted indications for drugs in this NDC category often exhibit increasing prevalence. For instance, if the medication addresses autoimmune diseases like rheumatoid arthritis or multiple sclerosis, the expanding patient population due to aging demographics compounds demand growth. According to the CDC, autoimmune condition prevalence has surged over the past decade, propelling demand for effective therapies [2].
Advances in Biotech and Personalized Medicine
Emerging biotechnologies and personalized treatment approaches have revolutionized how niche therapies are developed. Many drugs within this class are monoclonal antibodies or biologics, commanding premium prices attributable to complex manufacturing and novel mechanisms of action [3].
Regulatory Incentives and Market Access
Regulatory pathways such as orphan drug designation and breakthrough therapy status facilitate expedited approval processes and market exclusivity, incentivizing development and correlating with higher pricing strategies. These pathways often restrict generic entry, enabling sustained market control [4].
Competitive Landscape
The pharmaceutical market segment for NDC 67877-0659 features a mix of originator biologics, biosimilars, and emerging generics. Patent exclusivity and biologics’ complexity provide a competitive moat. Notably, biosimilar entrants typically emerge 8-12 years post-launch, influencing pricing dynamics [5].
Pricing Landscape and Historical Trends
Current Price Benchmarks
The current list and net prices for biologic therapies in comparable categories range significantly, often within the hundreds of thousands of dollars annually per patient. For instance, similar drugs targeted at autoimmune diseases can have annual treatment costs exceeding $50,000–$150,000 [6].
Price Factors and Reimbursement Dynamics
Factors influencing pricing include:
- Manufacturing complexity: Monoclonal antibodies and biologics have high production costs.
- Market exclusivity: Patent protections and regulatory exclusivities support premium pricing.
- Payer negotiations: PBMs and insurers negotiate rebates and discounts, impacting net prices.
- Patient affordability programs: Manufacturer assistance programs modulate out-of-pocket costs but may not influence overall list price.
Historical Price Trends
Over the past decade, biologics in similar categories have experienced initial high list prices, with subsequent moderate reductions through rebates and biosimilar competition. Nevertheless, the list prices tend to remain relatively stable, with net prices declining due to rebates and discounts. Unlike small molecules, biologics face slower erosion due to limited biosimilar penetration in certain markets [7].
Future Price Projections
Short-Term (1-3 Years)
In the near term, prices are expected to remain relatively stable, supported by patent exclusivity and limited biosimilar competition. Patent expirations are projected within the next five years, potentially catalyzing price erosion.
Medium to Long-Term (4-10 Years)
Post patent expiry, biosimilar policies in the U.S. are anticipated to expand market share, gradually driving list prices downward. However, the pace of biosimilar adoption is often slower compared to small molecules due to prescriber and payer barriers. Historically, biosimilar introduction has resulted in price reductions of approximately 15–30% [8].
Impact of Market Entry and Policy Changes
Regulatory and policy shifts, such as increased biosimilar reimbursement incentives or modifications to patent laws, could accelerate biosimilar uptake, further impacting pricing. Additionally, technological advancements like compounding and personalized medicine might influence future pricing paradigms.
Regulatory and Reimbursement Considerations
Regulatory exclusivities, patent litigations, and payer policies significantly influence the pricing landscape. The FDA approval process for biosimilars or next-generation formulations could add competitive pressure, affecting the drug’s gross and net prices.
State and federal programs, including Medicaid and Medicare, also exert pricing influence through formulary inclusion and rebate negotiations. The Drug Price Transparency Act and other recent policies aim to curb inflationary tendencies but have yet to significantly reshape biologic pricing structures [9].
Key Market Opportunities and Challenges
Opportunities:
- Market Expansion: Increasing prevalence of target conditions supports ongoing demand.
- Biosimilar Competition: Early biosimilar entrants could significantly reduce pricing if adopted effectively.
- Innovative Labeling: Extension of indications or combination therapies may enhance market share and justify higher prices.
Challenges:
- Patent Expiration: Patent losses threaten exclusivity and pricing power.
- Pricing Pressures: Payer pushback and premium prices may limit net revenue.
- Regulatory Bottlenecks: Delays in biosimilar approvals and uptake impede price reductions.
Conclusion and Strategic Implications
NDC 67877-0659 is positioned within a high-value, biologic-centered market characterized by prolonged patent protection and limited immediate biosimilar competition. Prices are expected to remain high in the short term, supported by regulatory exclusivity and market dynamics. However, over the next five years, patent expiry and biosimilar penetration are likely to exert downward pressure on list prices, necessitating strategic planning around lifecycle management and market differentiation.
Manufacturers and investors should monitor patent cliff timelines, engage in early biosimilar development, and leverage personalized medicine strategies to sustain profitability. Payers and policymakers’ evolving frameworks will also influence future pricing and reimbursement structures, requiring continuous market intelligence.
Key Takeaways
- The current market price of NDC 67877-0659 is supported by patent exclusivity, high manufacturing complexity, and limited biosimilar competition.
- Demand is driven by increasing disease prevalence, advances in personalized medicine, and regulatory incentives like orphan drug designation.
- Future price declines are anticipated post-patent expiry, with biosimilar competition potentially reducing prices by up to 30% within five years.
- Stakeholders should strategize around patent timelines, invest in lifecycle management, and prepare for regulatory shifts that could impact drug pricing.
- Monitoring payer negotiations and policy developments remains essential to optimize revenue and access strategies.
FAQs
1. When is patent expiration expected for NDC 67877-0659?
Patent expiration projections depend on the specific formulation and regulatory protections; generally, biologics receive 12 years of market exclusivity post-approval. Exact dates require review of patent filings and legal statuses.
2. How likely is biosimilar competition for this drug?
Given the biologic nature of similar therapies in its class, biosimilar entry is probable within 8–12 years of initial approval if patent protections lapse and regulatory pathways are pursued.
3. What is the impact of biosimilar entry on pricing?
Introduction of biosimilars typically results in a 15–30% reduction in list prices initially, with further discounts possible as market uptake expands.
4. Are there opportunities for value-based pricing for this drug?
Yes, especially if clinical outcomes are superior or demonstrated to reduce overall healthcare costs, enabling premium or value-based pricing models.
5. How does regulatory policy influence future pricing?
Policy initiatives aimed at promoting biosimilar adoption, reducing drug prices, or incentivizing innovation can significantly affect pricing strategies and market competition.
Sources
[1] FDA National Drug Code Directory. U.S. Food and Drug Administration.
[2] CDC. Autoimmune Diseases Data and Prevalence.
[3] IQVIA Biotech Reports. Current Trends in Biologics.
[4] FDA. Breakthrough Therapy Designation and Orphan Drug Incentives.
[5] IMPACT of Biosimilars on Market Prices. Journal of Pharmaceutical Policy.
[6] SSR Health. Biologic Drug Pricing Trends.
[7] CBO Report on Biologics and Biosimilars.
[8] FDA Biosimilar Approval and Market Trends.
[9] Congressional Budget Office. Drug Pricing Policy Overview.
More… ↓
